Andrew Cheng, President and CEO at Akero Therapeutics, Inc. (AKRO), sold 189,646 shares at $31.47 ($6.0M) on 2024-11-01, disclosed to the SEC on 2024-11-05.
Scheduled sale ($6.0M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.47 | 81,280 | $2.6M | 42.7% |
| 2 | $31.47 | 81,280 | $2.6M | 42.7% |
| 3 | $32.50 | 27,086 | $880K | 14.7% |
| Total | $31.62 avg | 189,646 | $6.0M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-13 | $2.9M | — | Filing → |
| AKRO | SELL | 2025-07-11 | $3.1M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $726K | — | Filing → |